Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Major Shareholder Sells $530,192.96 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) major shareholder Barry Canton sold 219,088 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $2.42, for a total value of $530,192.96. Following the transaction, the insider now owns 20,943,633 shares of the company’s stock, valued at $50,683,591.86. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Barry Canton also recently made the following trade(s):

  • On Monday, November 14th, Barry Canton sold 208,632 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.72, for a total value of $567,479.04.
  • On Thursday, November 10th, Barry Canton sold 186,028 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.46, for a total transaction of $457,628.88.
  • On Tuesday, November 8th, Barry Canton sold 193,616 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.46, for a total transaction of $476,295.36.
  • On Friday, November 4th, Barry Canton sold 204,906 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.51, for a total value of $514,314.06.
  • On Tuesday, November 1st, Barry Canton sold 196,308 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.77, for a total value of $543,773.16.
  • On Thursday, October 27th, Barry Canton sold 204,478 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.71, for a total value of $554,135.38.
  • On Monday, October 24th, Barry Canton sold 206,503 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.48, for a total transaction of $512,127.44.
  • On Thursday, October 20th, Barry Canton sold 196,721 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.47, for a total transaction of $485,900.87.
  • On Tuesday, October 18th, Barry Canton sold 198,051 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.64, for a total transaction of $522,854.64.
  • On Friday, October 14th, Barry Canton sold 215,948 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.62, for a total transaction of $565,783.76.

Ginkgo Bioworks Price Performance

Shares of DNA stock opened at $2.19 on Friday. The business has a fifty day simple moving average of $2.80 and a 200 day simple moving average of $2.84. The company has a market cap of $3.91 billion, a P/E ratio of -0.96 and a beta of 0.89. The company has a quick ratio of 11.78, a current ratio of 11.71 and a debt-to-equity ratio of 0.04. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $1.96 and a twelve month high of $13.74.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DNA. Captrust Financial Advisors boosted its stake in shares of Ginkgo Bioworks by 113.1% in the 3rd quarter. Captrust Financial Advisors now owns 38,885 shares of the company’s stock valued at $121,000 after purchasing an additional 20,635 shares in the last quarter. Advisory Research Inc. boosted its position in Ginkgo Bioworks by 21.3% in the third quarter. Advisory Research Inc. now owns 229,158 shares of the company’s stock valued at $715,000 after buying an additional 40,237 shares in the last quarter. Claraphi Advisory Network LLC bought a new stake in shares of Ginkgo Bioworks during the third quarter worth $34,000. Neuberger Berman Group LLC increased its holdings in shares of Ginkgo Bioworks by 2.8% during the third quarter. Neuberger Berman Group LLC now owns 1,757,421 shares of the company’s stock worth $5,483,000 after buying an additional 47,633 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Ginkgo Bioworks by 6.3% in the 3rd quarter. State Street Corp now owns 13,190,686 shares of the company’s stock valued at $41,155,000 after acquiring an additional 778,831 shares during the last quarter. Institutional investors and hedge funds own 53.37% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on DNA shares. Morgan Stanley began coverage on Ginkgo Bioworks in a research note on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 price objective on the stock. Raymond James decreased their price target on Ginkgo Bioworks from $14.50 to $10.50 and set an “outperform” rating on the stock in a research report on Wednesday. Finally, BTIG Research cut their price objective on shares of Ginkgo Bioworks to $4.00 in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Ginkgo Bioworks presently has an average rating of “Hold” and an average target price of $6.55.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.